Family Legacy Inc. Decreases Stock Holdings in CVS Health Co. (NYSE:CVS)

Family Legacy Inc. trimmed its position in shares of CVS Health Co. (NYSE:CVS) by 9.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,430 shares of the pharmacy operator’s stock after selling 1,006 shares during the quarter. Family Legacy Inc.’s holdings in CVS Health were worth $434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in CVS Health by 3.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 261,194 shares of the pharmacy operator’s stock valued at $16,424,000 after acquiring an additional 9,418 shares during the last quarter. Arete Wealth Advisors LLC purchased a new position in CVS Health during the 3rd quarter valued at approximately $1,369,000. Caisse DE Depot ET Placement DU Quebec raised its holdings in shares of CVS Health by 4.1% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,082,145 shares of the pharmacy operator’s stock worth $68,045,000 after acquiring an additional 42,307 shares in the last quarter. Edgestream Partners L.P. grew its stake in shares of CVS Health by 7.4% in the 3rd quarter. Edgestream Partners L.P. now owns 20,734 shares of the pharmacy operator’s stock worth $1,304,000 after buying an additional 1,437 shares in the last quarter. Finally, Cobblestone Capital Advisors LLC NY raised its position in CVS Health by 1.5% during the third quarter. Cobblestone Capital Advisors LLC NY now owns 133,848 shares of the pharmacy operator’s stock valued at $8,416,000 after purchasing an additional 1,947 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Price Performance

NYSE:CVS opened at $67.13 on Monday. CVS Health Co. has a one year low of $43.56 and a one year high of $79.98. The stock has a market cap of $84.64 billion, a PE ratio of 18.34, a P/E/G ratio of 0.98 and a beta of 0.54. The stock has a 50 day moving average price of $62.12 and a 200 day moving average price of $57.68. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities research analysts expect that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.96%. CVS Health’s dividend payout ratio is currently 72.68%.

Insider Activity at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CVS shares. Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Tuesday, December 3rd. StockNews.com raised shares of CVS Health from a “sell” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their target price on CVS Health from $80.00 to $81.00 and gave the company an “overweight” rating in a research report on Tuesday, February 18th. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Finally, UBS Group decreased their price target on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.